Top Analyst Picks for September 30

 BullPower
 
  BullPower
 
Follow  Message
 
 
 
BullPower charges through the market, spotlighting analyst upgrades and downgrades that signal key opportunities. With sharp insights and a bullish edge, BullBoost guides investors to smarter, profit-driven decisions.
 

•  30 Sep 2025
 

•   AARD  
   
  0.00%
•   COYA  
   
  0.00%
•   PEPG  
   
  0.00%
•   TNDM  
   
  0.00%
•   VKTX  
   
  0.00%

$VKTX commands attention with an extraordinary 271.08% upside projection from HC Wainwright, making Viking Therapeutics the most aggressive bullish call among today's upgrades. Trading at $26.28 with an RSI of 48.23, the stock sits in a downtrend but below its 50-day and 200-day moving averages, suggesting potential mean reversion opportunity. BTIG analyst Justin Zelin reiterated his $125 price target, emphasizing the company's strong positioning in the obesity and metabolic disease market. The significant gap between current trading levels and analyst targets reflects optimism about Viking's pipeline candidates, particularly as the obesity treatment space continues attracting intense investor interest following the success of GLP-1 medications.

$COYA presents another eye-catching opportunity with D. Boral Capital forecasting 199.40% upside for Coya Therapeutics. Currently priced at $5.70 with relatively light volume of 37.62K against an average of 98.77K, the stock trades in a downtrend with an RSI of 46.45. The biotechnology company's valuation appears compressed, creating what analysts view as a significant disconnect between market price and fundamental value. While the low trading volume suggests limited institutional attention currently, this same characteristic could amplify moves once catalysts emerge.

$AARD captures third place with Stifel's initiation at Buy and a 142.45% upside forecast. Aardvark Therapeutics trades at $13.29 with volume of 59.58K well below its 191.05K average, suggesting the new coverage could drive discovery by a broader investor base. The RSI of 68.67 indicates the stock has been building momentum, though it remains in sideways consolidation above its 20-day moving average of $10.04. Fresh analyst coverage often catalyzes increased institutional interest, particularly when accompanied by such substantial upside projections.

$PEPG offers 135% upside following its rating upgrade based on FREEDOM data. PepGen trades at $4.62 with strong uptrend momentum reflected in its 71.56 RSI and trading volume of 2.72M below the elevated 6.13M average. The stock has surged well above its moving averages, with its 20-day at $2.20 and 50-day at $1.69, indicating powerful recent appreciation. While the elevated RSI suggests the stock has moved significantly, the catalyst-driven upgrade based on clinical data provides fundamental support for the move.

$TNDM rounds out the top five with Canaccord Genuity's maintained Buy rating projecting 84.15% upside. Tandem Diabetes Care trades at $12.14 in a downtrend with an RSI of 46.31, sitting near its 20-day moving average of $12.23 but well below its 50-day of $13.30 and 200-day of $22.02. Volume of 1.18M runs below the 1.86M average, suggesting subdued interest that could shift with renewed catalysts. The diabetes care technology company's substantial disconnect from its 200-day average indicates significant technical damage that the analyst upgrade suggests may have created an oversold condition.

Bottom line :
$VKTX offers the most explosive upside potential at 271%, though the obesity treatment space carries execution risk and competition concerns.
$PEPG presents the most attractive technical setup with its strong uptrend, recent clinical data catalyst, and 135% upside target. The stock's momentum combined with fundamental validation from FREEDOM data creates a compelling risk-reward profile for those comfortable with biotechnology volatility.
$AARD deserves consideration for those seeking fresh institutional discovery potential, as Stifel's new coverage initiation with 142% upside could drive flows from investors previously unaware of the opportunity.

View All Headlines